Here are four things to know.
1. The study involved 240 healthy volunteers and was designed to demonstrate the GI safety superiority of ATB-346 compared to naproxen, the most prescribed nonsteroidal anti-inflammatory drug in the U.S.
2. ATB-346 is a hydrogen sulfide-releasing derivative of naproxen. While NSAIDs are the most commonly used therapy for osteoarthritis and are widely used in a variety of other conditions, their use is associated with a high incidence of GI ulceration and bleeding.
3. ATB-346 is intended to be an effective, GI-sparing anti-inflammatory/analgesic agent. It is Antibe’s leading drug.
4. Antibe anticipates being able to report top-line results during the week of March 19.
More articles on gastroenterology:
7 statistics on colorectal cancer in the US — 50k+ deaths expected in 2018
The Center for Digestive Health receives ASGE Endoscopy Unit Recognition
4 things to know about the mechanism that may underlie GI, other cancers
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
